文献速递骨质疏松与代谢性骨病小儿骨科

低磷酸酯酶症:临床表现及对阿司福酶α的治疗反应

Hypophosphatasia: presentation and response to asfotase alfa.
PubMed 文献 · Osteoporos Int · 2023-11-23

该研究报告7例低磷酸酯酶症(HPP)患者(5例儿童起病、2例成人起病),接受阿司福酶α(AA)6mg/kg/周治疗,平均随访6个月(SD=5)。患者主观报告肌肉力量、疼痛、步行距离及情绪精力等方面显著改善,注射部位反应为最常见不良反应,1例因轻微不良反应伴肌痛停药。

要点

  • 7例HPP患者接受AA 6mg/kg/周治疗,平均随访6个月(SD=5)。
  • 肌肉力量和疼痛主观改善最高达基线70%,步行距离改善最高达100%。
  • 注射部位反应为最常见不良反应,1例因轻微不良反应伴肌痛停药。

核心结论

  • HPP患者(儿童及成人起病)接受AA治疗后,肌肉骨骼和认知表现及生活质量获得显著主观改善。
  • 该药物在6例患者中耐受良好,1例因轻微不良反应伴肌痛而停药。

研究设计与样本

  • 研究纳入7例经DNA分析确诊的HPP患者(4女3男),年龄19-68岁,其中5例儿童起病、2例成人起病。
  • AA给药剂量为6mg/kg/周,平均随访6个月(SD=5)。

主要发现

  • 患者主观报告肌肉力量、肌肉疼痛、步行能力和步行距离改善,使用步行辅助器具减少。
  • 肌肉力量和疼痛较基线主观改善最高达70%,步行距离改善最高达100%。
  • 患者报告认知、情绪和精力水平改善,情绪改善最高达90%,精力水平改善最高达75%。
  • 6例患者中有4例在治疗3个月后首次注意到临床改善迹象。
  • 7例患者中有1例在AA治疗10个月时发生足趾骨折。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Hypophosphatasia (HPP) is a rare bone disease with limited scientific evidence on the tolerability and safety of its novel treatment, Asfotase Alfa (AA). We report 7 HPP patients' heterogenous presentations and the significant improvement in various clinical outcomes attained with AA shedding light on this highly effective and safe therapy. INTRODUCTION: Hypophosphatasia (HPP) is a rare inherited metabolic bone disorder characterized by a deficiency in the tissue non-specific alkaline phosphatase (TNSALP) due to loss of function mutation in the ALPL gene. HPP is associated with impaired skeletal mineralization due to elevations in inorganic pyrophosphate and altered phosphate : pyrophosphate ratio. Asfotase alfa (AA) "enzyme replacement" was approved for treatment of HPP in 2015. We present 7 patients with HPP, 5 with pediatric-onset, and 2 with adult-onset, who have been treated with AA and describe the efficacy and safety in these patients. METHODS: 7 patients (4 females, 3 males) aged 19-68 years with HPP were included in this study. Diagnosis of HPP was confirmed by DNA analysis. AA was administered in doses of 6mg/kg/week with a mean follow-up of 6 months (SD= 5). RESULTS: Subjective improvement in muscle strength, muscle pain, walking ability, and walking distance with a reduction in the use of gait aids was seen "with AA in HPP patients." Muscle strength and pain improved by up to 70% from baseline as quantified subjectively by patients. Walking distance improved by up to 100%. Patients also reported improved cognition, mood, and energy levels, with up to 90% improvement in mood and 75% improvement in energy levels. 4 out of 6 patients first noted clinical signs of improvement after 3 months of being on therapy. 1 out of the 7 patients sustained a toe fracture 10 months from being on AA. AA was well-tolerated with injection site reactions being the most reported adverse effect. CONCLUSION: HPP treatment with AA in individuals with both pediatric and adult-onset forms resulted in significant subjective improvement in musculoskeletal and cognitive manifestations in addition to patients' quality of life. The drug was well tolerated in 6 patients. 1 patient discontinued therapy because of minor adverse effects with myalgias.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Alsarraf F, Ali DS, Almonaei K, et al. Hypophosphatasia: presentation and response to asfotase alfa. Osteoporos Int. 2023. PMID: 37993691. doi:10.1007/s00198-023-06943-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。